Table 4.

Use of gastroprotection, transfusion requirements and length of hospitalisation with regard to gastropathy risk factors in patients admitted for non-steroidal anti-inflammatory drug (NSAID)-induced gastropathy

Risk factor	Patients, n (%)	Gastroprotection use, n (%)	p Value	Blood transfusion, n (%)	p Value	Mean (SD) hospital stay, days	p Value
Age
>60 years	37 (59.7)	18 (48.6)	0.001	21 (56.8)	0.026	6.1 (4.5)	0.022
≤60 years	25 (40.3)	2 (8.0)		7 (28.0)		4.1 (1.9)
Sex
Men	32 (51.6)	8 (25.0)	0.207	16 (50.0)	0.429	5.9 (4.6)	0.145
Women	30 (48.4)	12 (40.0)		12 (40.0)		4.5 (2.5)
Concomitant medication*
Yes	24 (38.7)	13 (54.2)	0.003	14 (58.3)	0.098	5.6 (3.0)	0.548
No	38 (61.3)	7 (18.4)		14 (36.8)		5.0 (4.2)
History†
Yes	9 (14.5)	6 (66.7)	0.017	5 (55.5)	0.498	5.8 (2.9)	0.659
No	53 (85.5)	14 (26.4)		23 (43.4)		5.2 (3.9)
Comorbidities‡
Yes	15 (24.2)	9 (60.0)	0.008	12 (80.0)	0.002	7.2 (2.9)	0.021
No	47 (75.8)	11 (23.4)		16 (34.0)		4.5 (3.8)

*Concomitant use of systemic corticosteroids, oral anticoagulants, clopidogrel or other NSAIDs (including ASA as antiplatelet).

†Personal medical history of peptic ulcer with/without complication (gastrointestinal bleeding, pyloric stenosis and perforation).

‡Cerebrovascular disease, chronic obstructive lung disease, cirrhosis, coronary disease, heart failure or renal failure.

ASA, acetylsalicylic acid.